05 July 2024
Insightful thought leadership article exploring current advances in technology that are helping improve cell analysis within drug discovery:
Click to read more
17 June 2024
Following the launch of our Celledonia™ benchtop cell analyser, Cytomos has been featured in several trade and science journals this month:
Click to read more
10 June 2024
Meet Celledonia™, the new and revolutionary benchtop cell analyser that will inform and expedite your bioprocesses and turn your data into actionable insights.
Click to read more
22 May 2024
At this year’s annual meeting of the International Society for Cell & Gene Therapy (ISCT), TechBio company Cytomos (www.cytomos.com) will be showcasing Celledonia™ – its flagship technology that utilises the company’s patented AuraCyt™ platform and is set to revolutionise complex biologics.
Click to read more
01 May 2024
Cytomos will be giving visitors to this year’s London Biotechnology Show a sneak preview of Celledonia™ – its flagship technology that utilises the company’s patented AuraCyt™ platform.
Click to read more
01 April 2024
Cytomos was featured in Genetic Engineering & Biotechnology News insights: Advancing Cell Analytics: A Vision for the Future (genengnews.com). Read full article below.
Click to read more
30 January 2024
Cytomos is pleased to announce that Dr Fernanda Masri, the company’s Chief Commercial and Innovation Officer, and former Head of Innovation Manufacturing and Collaborations at Cell and Gene Therapy Catapult, will co-chair the 2024 Biannual ECI Advancing Manufacture of Cell and Gene Therapies conference, taking place between 4th and 8th February 2024 in Coronado, California.
Click to read more
23 January 2024
Driving the commercialisation strategy as the company evolves from an R&D to a product-based business, Cytomos is pleased to announce the appointment of Dr Fernanda Masri as Chief Commercial and Innovation Officer and Dr Christel Fenge as Techno-Commercial Adviser.
Click to read more
21 December 2023
Cytomos has featured prominently in several trade and science journals this month, with articles on our AuraCyt™ cell analysis technology and our revamped website.
Click to read more
23 October 2023
Cytomos’ CSO, Dr. Lindsay Fraser, will highlight the benefits and full potential of Cytomos’ transformative AuraCyt™ technology and take questions from inquisitive delegates.
Click to read more
19 September 2023
Our appointment of industry leader Dr Sharon Brownlow as Non-Executive Director further enhances Cytomos’ senior management team and its unique value proposition to key industry markets.
Click to read more
10 April 2023
Thomas Clayton, Sevi Giakoumelou and Lindsay Fraser were delighted to attend the Midlothian & East Lothian Business Awards, organised by the Midlothian Chamber of Commerce.
Click to read more
20 December 2022
Following the successful £1.6m investment round in autumn, we feel privileged to announce that Innovate UK has awarded Cytomos with £500k from the latest SMART grant funding round as part of the UK Government investment strategy in developing technologies to transform health and social care.
Click to read more
14 September 2022
This £1.6m funding – led by Archangels, alongside Scottish Enterprise and Old College Capital – will enable the development and qualification of Cytomos Dielectric Spectroscopy (CDSTM) to move forward at pace and address the biopharma industry’s unmet needs.
Click to read more
05 September 2022
Gordon Sharp has joined the Executive team to lead our excellent Engineering team and continue working closely with the Scientific team.
Click to read more
02 September 2022
Lindsay joins the Executive team to lead our excellent Biology team and direct our scientific programme.
Click to read more
To find out more about our revolutionary biotechnology, please click below and complete our form.
[gravityform id="1" title="false"]